



Market Announcement

6 October 2022

Actinogen Medical Limited (ASX: ACW) – Trading Halt

Description

The securities of Actinogen Medical Limited ('ACW') will be placed in trading halt at the request of ACW, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 10 October 2022 or when the announcement is released to the market.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance (Sydney)



6 October 2022

Ms Lisa Banh
Adviser Listings ASX Compliance (Sydney)
20 Bridge Street
SYDNEY, NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for a trading halt

Actinogen Medical Limited ACN 086 778 476 (ASX: ACW) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

Pursuant to ASX Listing Rule 17.1, the Company requests the trading halt pending an announcement of the results of the Phase 2 biomarker study in people with mild Alzheimer's Disease.

We anticipate that the trading halt will be required until the earlier of the release of an announcement or no later than 10.00 am AEDT on Monday, 10 October 2022.

The Company is not aware of any reason why the trading halt should not be granted by ASX Limited.

Please contact me should you have any questions.

Yours sincerely

Peter Webse
Company Secretary

Authorised by the Board of Actinogen Medical